"The US Food and Drug Administration (FDA) has approved soluble ferric pyrophosphate (Triferic, Rockwell Medical) to replace iron and maintain hemoglobin in adults with chronic kidney disease who are undergoing dialysis.
Mircera overdosage can elevate hemoglobin levels above the desired level, which should be managed with discontinuation or reduction of Mircera dosage and/or with phlebotomy, as clinically indicated [see Pharmacodynamics]. Cases of severe hypertension have been observed following overdose with ESAs [see WARNINGS AND PRECAUTIONS].
Mircera is contraindicated in patients with:
- Uncontrolled hypertension [see WARNINGS AND PRECAUTIONS]
- Pure red cell aplasia (PRCA) that begins after treatment with Mircera or other erythropoietin protein drugs [see WARNINGS AND PRECAUTIONS]
- History of serious or severe allergic reactions to Mircera (e.g. anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria).
Last reviewed on RxList: 10/16/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Mircera Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.